Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-076528
Filing Date
2026-02-26
Accepted
2026-02-26 16:03:42
Documents
110
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K rgen-20251231.htm   iXBRL 10-K 4650022
2 EX-10.15 rgen-ex10_15.htm EX-10.15 272902
3 EX-21.1 rgen-ex21_1.htm EX-21.1 23703
4 EX-23.1 rgen-ex23_1.htm EX-23.1 7039
5 EX-31.1 rgen-ex31_1.htm EX-31.1 13920
6 EX-31.2 rgen-ex31_2.htm EX-31.2 13912
7 EX-32.1 rgen-ex32_1.htm EX-32.1 17916
8 GRAPHIC img3344002_0.jpg GRAPHIC 420335
  Complete submission text file 0001193125-26-076528.txt   23694459

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgen-20251231.xsd EX-101.SCH 2749937
113 EXTRACTED XBRL INSTANCE DOCUMENT rgen-20251231_htm.xml XML 5374869
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-14656 | Film No.: 26687700
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)